The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Lilly
Stock and Other Ownership Interests - Lilly
RELAY+: Exploratory study of ramucirumab plus gefitinib in untreated patients (pts) with epidermal growth factor receptor (EGFR)-mutated metastatic non-small cell lung cancer (NSCLC).
 
Makoto Nishio
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AbbVie; AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Teijin Pharma
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Lilly (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Kazuto Nishio
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Eisai; Guardant Health; Life Technologies; Life Technologies; Lilly Japan; MSD; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Roche; Sanofi; Solasia Pharma; SymBio Pharmaceuticals; Yakult Honsha
 
Martin Reck
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck Serono; MSD Oncology; Novartis; Pfizer; Roche/Genentech
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck Serono; MSD Oncology; Novartis; Pfizer; Roche/Genentech
 
Edward B. Garon
Consulting or Advisory Role - Dracen; EMD Serono; GlaxoSmithKline; Novartis
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dynavax Technologies (Inst); EMD Serono (Inst); Genentech (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Neon Therapeutics (Inst); Novartis (Inst)
 
Fumio Imamura
Honoraria - AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca
Research Funding - AstraZeneca; Boehringer Ingelheim; Ono Pharmaceutical
 
Tomoya Kawaguchi
Honoraria - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Hiroyuki Yamaguchi
Honoraria - Boehringer Ingelheim; Bristol-Myers Squibb; Lilly
Research Funding - Boehringer Ingelheim; Lilly; Novartis
 
Satoshi Ikeda
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical
 
Katsuya Hirano
Honoraria - AstraZeneca; Chugai Pharma; Lilly Japan; Nippon Boehringer Ingelheim; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Kissei Pharmaceutical (Inst); Lilly (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Carla M Visseren-Grul
No Relationships to Disclose
 
Ryan C Widau
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Annamaria H. Zimmermann
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Gosuke Homma
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Sotaro Enatsu
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Kazuhiko Nakagawa
Honoraria - Abbvie; Astellas Pharma; AstraZeneca Japan; Bayer Yakuhin; Bristol-Myers Squibb; CareNet; Chugai Pharma; Daiichi Sankyo; Hisamitsu Pharmaceutical; Kyorin; Kyorin; Lilly; Medical Review Co., Ltd.; Medicus Shuppan Publishers; Medicus Shuppan Publishers; Merck; MSD K.K; NANZANDO Co.,Ltd.; Nichi-iko; Nikkei Business Publications, Inc; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Roche; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific; YODOSHA; Yomiuri Telecasting Corporation
Consulting or Advisory Role - Kyorin; Lilly; Ono Pharmaceutical; Pfizer; Takeda
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca Japan (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); CMIC (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EPS Holdings (Inst); EPS International (Inst); ICON Clinical Research (Inst); IQvia (Inst); Kissei Pharmaceutical (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Serono (Inst); MSD K.K (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); PAREXEL International Corp. (Inst); Pfizer (Inst); Pfizer (Inst); SymBio Pharmaceuticals (Inst); Syneos Health (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)